1. Anderson EC, Svedsen P, Svejgaard A, Holmdahl R, Fugger L (2000) A molecular basis for the HLA association in rheumatoid arthritis. Rev Immunogen 2:81–87
2. Arnett FC, Edwothy SM, Bloch DA et al. (1988) American Rheumatism Association 1987 revised criteria form classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
3. Abouac J, Gossec L, Dougados M (2006) Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis – a systemic literature review. Ann Rheum Dis 65:845–851
4. Breedveld FC, Rau R, Van Riel PLC, Van de Putte LBA, Schattenkirchner M, Kupper H, Segurado OG (2004) Long-term remission, efficacy and safety in patients with rheumatoid arthritis treated with adalimumab (HUMIRA) plus methotrexate for more than 5 years. Abstract EULAR p 5, Ann Rheum Dis, 63, 2004, Suppl. 1, p. 268
5. Breedveld FC, Weisman MH, Kavanaugh AF et al. (2006) A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37